Compugen Ltd. - Ordinary Shares (CGEN) News

Compugen Ltd. - Ordinary Shares (CGEN): $1.98

0.00 (-0.06%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add CGEN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#27 of 359

in industry

Filter CGEN News Items

CGEN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CGEN News Highlights

  • CGEN's 30 day story count now stands at 8.
  • Over the past 16 days, the trend for CGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about CGEN are PRE, AZN and EVGN.

Latest CGEN News From Around the Web

Below are the latest news stories about COMPUGEN LTD that investors may wish to consider to help them evaluate CGEN as an investment opportunity.

Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More

Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.

Yahoo | December 21, 2023

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.

Yahoo | December 20, 2023

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...

Yahoo | December 20, 2023

Why Are Stocks Up Today?

Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday!

William White on InvestorPlace | December 19, 2023

Why Is Compugen (CGEN) Stock Up 189% Today?

Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.

William White on InvestorPlace | December 19, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!

William White on InvestorPlace | December 19, 2023

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The

Yahoo | December 19, 2023

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to tre

Yahoo | December 19, 2023

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

FOSTER CITY, Calif. & HOLON, Israel, December 19, 2023--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Yahoo | December 19, 2023

7 Promising Penny Stocks With the Potential to Defy Expectations

You know you want it.

Josh Enomoto on InvestorPlace | December 15, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!